Threat of Dengue to Blood Safety in Dengue-Endemic Countries by Wilder-Smith, Annelies et al.
Dengue, the most common arbovirus infection glob-
ally, is transmitted by mosquito vectors. Healthcare-related 
transmission, including transmission by blood products, has 
been documented, although the frequency of these occur-
rences is unknown. Dengue is endemic to Singapore, a city-
state in Asia. Using mathematical modeling, we estimated 
the risk for dengue-infected blood transfusions in Singapore 
in 2005 to be 1.625–6/10,000 blood transfusions, assuming 
a ratio of asymptomatic to symptomatic infections of 2:1 to 
10:1. However, the level of viremia required to cause clinical 
dengue cases is person-dependent and unknown. Further 
studies are needed to establish the magnitude of the threat 
that dengue poses to blood safety in countries where it is 
endemic. It will then be possible to assess whether screen-
ing is feasible and to identify approaches that are most cost-
effective on the basis of characteristics of local populations 
and seasonality of dengue.
E
merging infectious diseases pose threats to the gen-
eral human population, including recipients of blood 
transfusions. Dengue is an expanding problem in tropical 
and subtropical regions and is now the most frequent ar-
boviral disease in the world, with an estimated annual 100 
million cases of dengue fever, 250,000 cases of dengue 
hemorrhagic fever, and 25,000 deaths per year (1). Den-
gue virus infections have been reported in >100 countries; 
2.5 billion people live in areas where dengue is endemic 
(1). It is also increasingly reported to occur in interna-
tional travelers (2). Dengue is of major international pub-
lic health concern because of the expanding geographic 
distribution of the virus and competent mosquito vectors, 
increased frequency of epidemics, cocirculation of mul-
tiple virus serotypes, and emergence of dengue hemor-
rhagic fever in new areas.
Dengue virus belongs to the family Flaviviridae and is 
transmitted by mosquitoes of the genus Aedes (1). Flavivi-
ruses are small, lipid-enveloped, positive-stranded RNA vi-
ruses (1). Dengue infection has a viremic phase that lasts 4–8 
days (3), and most infections remain subclinical (4). Viremia 
can precede the onset of symptoms in persons with clinical 
disease. Plasma viral RNA levels range from 105.5 to 109.3 
copies/mL, and blood collected during this phase may be in-
fective when transfused into susceptible hosts (5).
A literature search conducted in March 2008 on blood 
transfusion and dengue did not identify any published re-
ports of blood transfusion–associated dengue in dengue-
endemic countries. Healthcare-associated transmission is 
difﬁ  cult to ascertain in dengue-endemic countries, although 
there is 1 report of possible transmission of dengue in a 
healthcare setting in Hong Kong, Special Administrative 
Region, People’s Republic of China, attributed to a viremic 
resident of Hong Kong (6). In contrast, healthcare-acquired 
dengue infections in countries in which dengue is not en-
demic can be determined. Several reports have described 
travelers who returned from dengue-endemic countries to 
those not endemic for dengue and transmitted dengue in-
fection to healthcare workers by needlestick injury or mu-
cocutaneous exposure to blood (7,8).
Healthcare-associated transmission of viruses among 
humans has been recently reviewed for dengue and other 
ﬂ  aviviruses such as West Nile virus (WNV) and yellow 
fever virus (9). Routes of transmission include percutane-
ous, mucous membrane, bone marrow transplant, organ 
transplant, hemodialysis, and transfusion of blood products 
(6–8,10–25) (Table) However, despite good evidence for 
its transmission in healthcare settings, dengue is currently 
not considered a risk to blood safety.
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We draw parallels from recent experiences with West 
Nile fever and encephalitis in the United States. WNV ﬁ  rst 
appeared in the United States in 1999 and has since spread 
throughout the country, resulting in thousands of cases of 
disease (26). Approximately 80% of WNV infections are 
asymptomatic (27). By 2002, 23 patients in the United States 
were conﬁ  rmed to have acquired WNV through transfused 
blood and blood products (erythrocytes, platelets, and fresh-
frozen plasma) (23). The estimated risk for virus transmis-
sion through transfusion during the 1999 WNV epidemic in 
New York was 1.8/10,000–2.7/10,000 donations, and ≈2.0 
viremic donations/10,000 donors in the borough of Queens 
(28). Of the 2.5 million blood donations screened for WNV 
from June through December 2003, 0.05% were positive 
at the ﬁ  rst screening and 0.02% were conﬁ  rmed (29). In 
response to these ﬁ  ndings, by 2003, essentially all blood 
donations in the United States were being tested for WNV. 
In contrast, no screening of blood products is conducted for 
dengue, although dengue virus is estimated to affect >100 
million persons annually in tropical and subtropical regions. 
A recent study in Puerto Rico reported nucleic acid testing 
for dengue virus in the blood supply and found the viral 
RNA prevalence to be 7.3/10,000 U of blood donations, 
which approximates the prevalence of WNV in the United 
States during the transmission season (30). In addition, 
screening of donors in Honduras and Brazil has identiﬁ  ed 
dengue virus RNA (0.37% and 0.06% of blood donations 
or 37/10,000 and 6/10,000 blood donations, respectively) 
by using a transcription-mediated ampliﬁ  cation assay (31).
We postulate that dengue virus poses a greater threat 
worldwide to blood safety than WNV but that this hypoth-
esis has been neglected because dengue occurs predomi-
nantly in developing countries. We used mathematical 
modeling to estimate the risk for dengue in Singapore. Sin-
gapore is an industrialized Asian city-state in which dengue 
is endemic. This city-state has the capacity to implement 
blood screening for dengue. The dengue seroprevalence 
rate in the adult population in Singapore, which has a popu-
lation of ≈4 million persons, is 45% (32). In 2005, 14,209 
cases of symptomatic dengue infections were reported in 
Singapore, a large proportion (≈80%) of which were in 
adolescents or adults (33). We calculated the force of in-
fection in this population. The force of infection is deﬁ  ned 
as follows: per capita new cases in a ﬁ  nite period = rate 
of contacts by potentially infective persons × (no. viremic 
persons in a population in a ﬁ  nite period/total population in 
a ﬁ  nite period).
If one assumes that there were 11,367 reported adult 
cases in Singapore in 2005 (80% of 14,209) and a ratio of 
asymptomatic to symptomatic cases of 2:1, a total of 34,101 
viremic adults in 2005 would have viremia that lasts <1 
week. This ﬁ  nding indicates there would be 656 infective 
persons per week, which translates to 0.00016 viremic per-
sons in a ﬁ  nite period per total population in a ﬁ  nite period. 
If one considers that there are ≈80,000 blood transfusions 
in Singapore per year, there would be 1,538 transfusions 
per week. Therefore, the force of infection for 2005 in Sin-
gapore was ≈13 infective blood donations.
However, if we assume a ratio of asymptomatic to 
symptomatic cases of 10:1, we then have 125,037 viremic 
persons, or ≈2,405 infective persons per week. This ﬁ  nding 
indicates that the number of viremic persons in the popu-
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Table. Reported healthcare-associated transmission of flaviviruses 
Virus Route of transmission  Comment References
Dengue Percutaneous Several healthcare workers were infected after needlestick injuries during 
care of returned travelers who had diagnoses of dengue. 
(8,10–13)
Mucocutaneous A healthcare worker became infected with dengue 3 virus after being 
splashed in the face by blood from a febrile traveler who had a diagnosis of 
dengue.
(7,14)
Blood transfusion  A 17-year-old man from Hong Kong, Special Administrative Region, 
People’s Republic of China, donated blood in July 2002, from which 
erythrocytes were transfused to a 72-year-old woman, in whom febrile 
illness consistent with dengue fever developed 3 d later. 
(15)
Bone marrow transplant  A 6-year-old child from Puerto Rico became infected with dengue 4 virus 
from a bone marrow transplant and died. 
(16)
Renal transplant  Dengue hemorrhagic fever developed after a living donor renal transplant.  (17)
Yellow fever  Laboratory  A laboratory technician acquired yellow fever after obtaining blood and 
performing a blood count on a yellow fever patient; he died subsequently. 
Yellow fever was transmitted to at least 30 other scientists and laboratory 
workers after contact with mouse or monkey blood or tissues or handling 
infected animals. 
(18–20)
West Nile  Percutaneous Virus was transmitted to 2 microbiologists by laceration or needlestick 
injuries in laboratory. 
(21)
Transfusion Virus was transmitted to numerous recipients of blood products.  (22,23)
Organ transplant  Virus was transmitted to transplant recipients from kidneys, liver, and heart 
of an infected donor. 
(24)
Hemodialysis  Virus infection in a cluster of 3 hemodialysis patients suggested 
transmission through a common dialysis machine. 
(25)PERSPECTIVES
lation in a ﬁ  nite period/total population in a ﬁ  nite period 
is 0.00060115. We would then end up with a force of in-
fection for 2005 of 48 infective donations. Depending on 
the ratio of asymptomatic to symptomatic infections, there 
were ≈13–48 dengue infected blood donations in Singa-
pore in 2005. With ≈80,000 blood transfusions annually 
in Singapore, the proportion of infected blood transfusions 
would be ≈1.625–6/10,000 transfusions, which is consis-
tent with reported dengue RNA prevalence in blood dona-
tions in Puerto Rico, Brazil, and Honduras (30,31). This 
proportion is similar or even higher than the estimated risk 
for WNV transmission by transfusion during the 1999 epi-
demic in New York, which was reported to be 1.8/10,000–
2.7/10,000 donations (28). A total of 1.625–6/10,000 blood 
transfusions would translate to 3.25–12 potentially infec-
tive blood transfusions/1 million persons in Singapore, if 
one assumes a ratio of asymptomatic to symptomatic case 
between 2:1 and 10:1. Further, a recent report provides 
well-documented evidence of a cluster of blood transfu-
sion–associated dengue infections in Singapore (34).
Why has transfusion-associated dengue not yet been 
widely recognized as a problem in dengue-endemic coun-
tries? Lack of recognition is likely due to lack of aware-
ness that dengue is transmitted not only by vectors but also 
by blood products. Because of the effects of infection and 
recurring epidemics in dengue-endemic countries, isolated 
cases of healthcare-acquired infections will go unnoticed. In 
many healthcare facilities, patients are not protected from 
mosquitoes, and it is therefore difﬁ  cult to ascertain whether 
infections were related to blood transfusions or exposure to 
vectors. Further, risk for transmission by transfusion may 
depend on the level of viremia, which has been shown to 
correlate with severity of disease (35). It is likely, although 
not proven, that viremia is lower and shorter in duration in 
asymptomatic persons than in symptomatic persons. The 
risk for transfusion-associated dengue will vary greatly 
from 1 country to another, depending on the epidemiologic 
pattern of dengue and the immunity level in the population. 
In countries where dengue is mainly a childhood disease, 
risk for blood transfusion–transmitted dengue will be lower 
because of lack of overlap of infected and blood-donating 
populations. However, risk for nosocomial transmission 
from needlesticks and other blood exposures would exist in 
all areas with dengue.
Blood transfusion–related dengue will likely repre-
sent only a small proportion of all dengue cases in dengue-
endemic countries. Screening blood for dengue antigens 
in dengue-endemic countries would be costly and should 
therefore be recommended only after careful assessment 
of risk for infection and cost per blood product–associat-
ed dengue infection averted. Therefore, the ﬁ  rst step is to 
quantify this risk in a systematic study. Risk will vary by 
geographic region and season and may change over time. 
We suggest targeted nucleic acid ampliﬁ  cation testing of 
individual donations in high-prevalence regions, a strategy 
that was implemented successfully for screening of WNV 
in the United States in 2004 (36); nucleic acid ampliﬁ  ca-
tion tests of minipools of several samples of donated blood 
have also been proposed (36). A prototype nucleic acid 
test, which is suitable for high-throughput screening, has 
been developed for detection of dengue virus RNA in blood 
donations (31). The initial study should be conducted dur-
ing the dengue transmission season to identify maximum 
incidence of viremic donations. This testing would pro-
vide a baseline estimate of risk for transmission of infec-
tive blood. If the risk is found to be substantial, healthcare 
providers would need to decide at what threshold screen-
ing should be instituted. Policies will also be inﬂ  uenced by 
economic resources available and healthcare priorities of a 
country or region.
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